Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and metaanalysis

Annals of Internal Medicine

Volumn 163, Issue 7, 2015, Pages 519-528

  Siemieniuk, Reed A C ^a   Meade, Maureen O ^a   Alonso Coello, Pablo ^a   Briel, Matthias ^a   Evaniew, Nathan ^a   Prasad, Manya ^a   Alexander, Paul E ^a   Fei, Yutong ^a   Vandvik, Per O ^a   Loeb, Mark ^a   Guyatt, Gordon H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; HYDROCORTISONE; PREDNISOLONE; PREDNISONE;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; ATTRIBUTABLE RISK; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DRUG INDUSTRY; EVIDENCE BASED PRACTICE; GASTROINTESTINAL HEMORRHAGE; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LENGTH OF STAY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PREGNANT WOMAN; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CAUSE OF DEATH; CHEMICALLY INDUCED; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; FEMALE; INTENSIVE CARE; MALE; META ANALYSIS; MIDDLE AGED; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME, ADULT;

ADRENAL CORTEX HORMONES; CAUSE OF DEATH; CHEMOTHERAPY, ADJUVANT; COMMUNITY-ACQUIRED INFECTIONS; CRITICAL CARE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERGLYCEMIA; LENGTH OF STAY; MALE; MIDDLE AGED; PNEUMONIA; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84941368693     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0715     Document Type: Review

References (57)

1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117-71. [PMID: 25530442] doi:10.1016/S0140-6736(14)61682-2
2. Estenssoro E, Dubin A, Laffaire E, Canales H, Sá enz G, Moseinco M, et al. Incidence, clinical course, and outcome in 217 patients with acute respiratory distress syndrome. Crit Care Med. 2002;30:2450-6. [PMID: 12441753]
3. Thomas CP, Ryan M, Chapman JD, Stason WB, Tompkins CP, Suaya JA, et al. Incidence and cost of pneumonia in Medicare beneficiaries. Chest. 2012;142:973-81. [PMID: 22406959]
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71-9. [PMID: 20729232] doi:10.1136/thx.2009.129502
5. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 2009;374:1543-56. [PMID: 19880020] doi:10.1016/S0140-6736(09)61114-4
6. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol. 2008;8:776-87. [PMID: 18802444] doi:10 .1038/nri2402
7. Ferguson ND, Cook DJ, Guyatt GH, Mehta S, Hand L, Austin P, et al; OSCILLATE Trial Investigators. High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med. 2013;368: 795-805. [PMID: 23339639] doi:10.1056/NEJMoa1215554
8. Erickson SE, Martin GS, Davis JL, Matthay MA, Eisner MD; NIH NHLBI ARDS Network. Recent trends in acute lung injury mortality: 1996-2005. Crit Care Med. 2009;37:1574-9. [PMID: 19325464] doi: 10.1097/CCM.0b013e31819fefdf
9. Piantadosi CA, Schwartz DA. The acute respiratory distress syndrome. Ann Intern Med. 2004;141:460-70. [PMID: 15381520] doi:10 .7326/0003-4819-141-6-200409210-00012
10. Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, et al. Role of glucocorticoids on inflammatory response in nonimmuno-suppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218-20. [PMID: 10489855]
11. Remmelts HH, Meijvis SC, Biesma DH, van Velzen-Blad H, Voorn GP, Grutters JC, et al. Dexamethasone downregulates the systemic cytokine response in patients with community-acquired pneumonia. Clin Vaccine Immunol. 2012;19:1532-8. [PMID: 22855392] doi:10 .1128/CVI.00423-12
12. Nie W, Zhang Y, Cheng J, Xiu Q. Corticosteroids in the treatment of community-acquired pneumonia in adults: a meta-analysis. PLoS One. 2012;7:e47926. [PMID: 23112872] doi:10.1371/journal.pone .0047926
13. Chen Y, Li K, Pu H, Wu T. Corticosteroids for pneumonia. Co-chrane Database Syst Rev. 2011:CD007720. [PMID: 21412908] doi: 10.1002/14651858.CD007720.pub2
14. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al; Infectious Diseases Society of America. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72. [PMID: 17278083]
15. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al; Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections-full version. Clin Microbiol Infect. 2011;17 Suppl 6:E1-59. [PMID: 21951385] doi:10.1111/j.1469-0691.2011.03672.x
16. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2015;385:1511-8. [PMID: 25608756] doi:10.1016/S0140-6736(14)62447-8
17. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313: 677-86. [PMID: 25688779] doi:10.1001/jama.2015.88
18. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommenda-tions.BMJ.2008;336:924-6.[PMID:18436948]doi:10.1136/bmj.39489 .470347.AD
19. Busse JW, Guyatt G. Modification of Cochrane tool to assess risk of bias in randomized trials. 2013. Accessed at https://distillercer. com/wp-content/uploads/2014/02/Tool-to-Assess-Risk-of-Bias-in -Randomized-Controlled-Trials.docx on 24 June 2015.
20. Akl EA, Johnston BC, Alonso-Coello P, Neumann I, Ebrahim S, Briel M, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One. 2013;8:e57132. [PMID: 23451162] doi:10.1371/journal.pone .0057132
21. Ebrahim S, Johnston BC, Akl EA, Mustafa RA, Sun X, Walter SD, et al. Addressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol. 2014;67:560-70. [PMID: 24613497] doi:10.1016/j.jclinepi.2013.11.014
22. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol. 2011;64:1283-93. [PMID: 21839614] doi:10 .1016/j.jclinepi.2011.01.012
23. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135. [PMID: 25524443] doi:10.1186/1471-2288-14-135
24. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242-8. [PMID: 15557131]
25. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-50. [PMID: 8995086]
26. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377-82. [PMID: 12728155]
27. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax. 2001;56 Suppl 4:IV1-64. [PMID: 11713364]
28. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al; American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-54. [PMID: 11401897]
29. Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis. 1993;148:1418-26. [PMID: 8239186]
30. Higgins JPT, Altman DG. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. Chichester, United Kingdom: J Wiley; 2009.
31. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik- Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. [PMID: 24548571] doi:10.1186/1471-2288-14-25
32. Knapp G, Hartung J. Combined test procedures in the meta-analysis of controlled clinical trials. Stud Health Technol Inform. 2000;77:34-8. [PMID: 11187570]
33. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furu-kawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol. 2013;66:173-83. [PMID: 23116689] doi:10.1016/j.jclinepi .2012.08.001
34. Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137-43. [PMID: 23110409] doi:10.1111/j.1532-5415.2012.04208.x
35. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, et al; Australian Community-Acquired Pneumonia Study Collaboration. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47:375-84. [PMID: 18558884] doi:10.1086 /589754
36. Toba A, Yamazaki M, Mochizuki H, Noguchi T, Tsuda Y, Kawate E, et al. Lower incidence of acute respiratory distress syndrome in community-acquired pneumonia patients aged 85 years or older. Respirology. 2010;15:319-25. [PMID: 20070586] doi:10.1111/j .1440-1843.2009.01685.x
37. Capelastegui A, España Yandiola PP, Quintana JM, Bilbao A, Diez R, Pascual S, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009;136:1079-85. [PMID: 19395580] doi:10 .1378/chest.08-2950
38. Tikkinen KA, Agarwal A, Craigie S, Cartwright R, Gould MK, Haukka J, et al. Systematic reviews of observational studies of risk of thrombosis and bleeding in urological surgery (ROTBUS): introduction and methodology. Syst Rev. 2014;3:150. [PMID: 25540016] doi: 10.1186/2046-4053-3-150
39. Wagner HN Jr, Bennett IL Jr, Lasagna L, Cluff LE, Rosenthal MB, Mirick GS. The effect of hydrocortisone upon the course of pneumo-coccal pneumonia treated with penicillin. Bull Johns Hopkins Hosp. 1956;98:197-215. [PMID: 13304518]
40. El-Ghamrawy AH, Shokeir MH, Esmat AA. Effects of low-dose hydrocortisone in ICU patients with severe community-acquired pneumonia. Egyptian Journal of Chest. 2006;55:91-9.
41. Nafae RM, Ragab MI, Amany FM, Rashed SB. Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia. Egyptian Journal of Chest Diseases and Tuberculosis. 2013;62 :439-45.
42. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975-82. [PMID: 20133929] doi:10.1164/rccm.200905 -0808OC
43. Meijvis SC, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, van Velzen-Blad H, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377:2023-30. [PMID: 21636122] doi:10.1016/S0140-6736(11)60607-7
44. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirota N, Yama-guchi H, et al. Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung. 2007;185:249-55. [PMID: 17710485]
45. McHardy VU, Schonell ME. Ampicillin dosage and use of pred-nisolone in treatment of pneumonia: co-operative controlled trial. Br Med J. 1972;4:569-73. [PMID: 4404939]
46. Fernández-Serrano S, Dorca J, Garcia-Vidal C, Fernández-Sabé N, Carratalà J, Fernández-Agüera A, et al. Effect of corticosteroids on the clinical course of community-acquired pneumonia: a randomized controlled trial. Crit Care. 2011;15:R96. [PMID: 21406101] doi: 10.1186/cc10103
47. Sabry NA, Omar EE. Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm. 2011;2:73-81.
48. Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson DW. Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993; 104:389-92. [PMID: 8339624]
49. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818-24. [PMID: 7509706]
50. Montori VM, Devereaux PJ, Adhikari NK, Burns KE, Eggert CH, Briel M, et al. Randomized trials stopped early for benefit: a systematic review. JAMA. 2005;294:2203-9. [PMID: 16264162]
51. Bassler D, Briel M, Montori VM, Lane M, Glasziou P, Zhou Q, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303:1180-7. [PMID: 20332404] doi:10.1001/jama.2010.310
52. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116:78-84. [PMID: 1530753] doi:10.7326 /0003-4819-116-1-78
53. Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117. [PMID: 20354011] doi:10.1136/bmj .c117
54. Cheng M, Pan ZY, Yang J, Gao YD. Corticosteroid therapy for severe community-acquired pneumonia: a meta-analysis. Respir Care. 2014;59:557-63. [PMID: 24046464] doi:10.4187/respcare.02758
55. Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014; 9:CD001288. [PMID: 25178099] doi:10.1002/14651858.CD001288 .pub4
56. Peter JV, John P, Graham PL, Moran JL, George IA, Bersten A. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ. 2008;336: 1006-9. [PMID: 18434379] doi:10.1136/bmj.39537.939039.BE
57. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA. Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest. 1987;92:1032-6. [PMID: 3315478]